Influence of Adipocytokines and Periprostatic Adiposity Measurement Parameters on Prostate Cancer Aggressiveness

  • Zhang, Qiang (Department of Urology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Sun, Li-Jiang (Department of Urology, The Affiliated Hospital of Qingdao University Medical College) ;
  • Qi, Jun (Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine) ;
  • Yang, Zhi-Gang (Department of Urology, Baotou City Central Hospital) ;
  • Huang, Tao (Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine)
  • Published : 2014.02.28


Background: The relationship between obesity and prostate cancer aggressiveness is controversial in recent studies, partly because BMI is the only generally applied marker of obesity. Our study aimed at evaluating the correlation of periprostatic fat (PF) on magnatic resonance imaging (MRI) and adipocytokines with prostate cancer aggressiveness. Patients and method: A total of 184 patients who underwent radical retropubic prostatectomy (RRP) were analyzed retrospectively; different fat measurements on MRI slices and levels of adipocytokines were compared with the clinical and pathologic factors using SSPS ver.13.0. Result: The PF rates showed a statistically significant variation (p=0.019, 0.025) among groups, that is to say, more adipose tissue was distributed in periprostatic areas of high risk patients. Logistic regression analysis adjusted for age revealed a statistically association between the PF, the ratio and the risk of having high-risk disease (p=0.031, 0.024). The levels of IL-6, leptin and c-reactive protein (CRP) significantly increased with the aggressiveness of prostate cancer, and also with PF and its ratio. The strongest correlation was seen between IL-6 and PF (Pearson r coefficient=0.67, P<0.001). No association was observed between adipocytokines and BMI. Conclusion: Periprostatic adiposity not only affects prostate cancer aggressiveness, but also influences the secretion of adipocytokines. IL-6, PF and CRP have promoting effects on progression of prostate cancer.


  1. Von HP, Pina F, Perez A, et al (2004). Visceral fat accumulation as a risk factor for prostate cancer. Obes Res, 12, 1930-5.
  2. Van Roermund JG, Hinnen KA, Tolman CJ, et al (2011). Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients. BJUI Int, 107, 1775-9.
  3. Van Romermund JG, Bol GH, Witjes JA, et al (2010). Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness. World J Urol, 28, 699-704.
  4. Vol Hafe P, Pina F, Perez A, et al (2004). Visceral fat accumulation as a risk factor for prostate cancer. Obes Res, 12, 1930-5.
  5. Tang Z-L, Bai J, Gu L-N (2013). A systematic review: epidemic status of prostate Cancer and Breast Cancer from 2000 to 2010 in China. China Cancer, 4, 260-5.
  6. Rodrigues C, Freedland SJ, Deka A, et al (2007). Body mass index, weight change, and risk of prostate cancer in the cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev, 16, 63-9.
  7. Saglam K, Aydur E, Yilmaz M, et al (2003). Leptin influences cellular differentiation and progression in prostate cancer. J Urol, 169, 1308-11.
  8. Stark JR, Li H, Kraft P, et al (2009). Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer, 124, 2683-9.
  9. Tewari R, Rajender S, Natu SM, et al (2013). Significance of obesity markers and adipocytokines in high grad and high stage prostate cancer in North Indian men-A cross-sectional study. Cytokine, 63, 130-4.
  10. Tobias P, Ute N, Heiner B (2008). Obesity and cancer. Proc Nutr Soc, 67, 128-45.
  11. Van Roermund JG, Hinnen KA, Battermann JJ, et al (2009). Kiemeney LA. Body mass index is not a prognostic marker for prostate specific antigen failure and survival in Dutch men treated with brachytherapy. BJU Int, 105, 42-8.
  12. McGrowder DA, Jackson LA, Crawford TV (2012). Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev, 13, 1-13.
  13. Mallah KN, DiBlasio CJ, Rhee AC, et al (2005). Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer, 103, 2030-4.
  14. Amling CL, Riffenburgh RH, Sun L, et al (2004). Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol, 22, 439-45.
  15. Ann W, Lori C, Steamson C (2007). Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr, 86, 843-57.
  16. Merrick GS, Galbreath RW, Butler WM, et al (2007). Obesity is not predictive of overall survival following permanent prostate brachytherapy. Am J Clin Oncol, 30, 588-96.
  17. Mistry T, Digby JE, Desai KM, et al (2007). Obesity and prostate cancer: a role for adipokines. Eur Urol, 52, 46-53.
  18. Mucksavage P, Mitchell C, Kutikov A, et al (2012). Anthropometric difference in obese men with biochemical failure after radical retropubic prostatectomy. Urol Oncol, 30, 590-5.
  19. Ouchi N, Kihara S, Funahashi T, et al (2003). Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation, 107, 671-4.
  20. Prins RC, Rademacher BL, Mongoue-Tchokote S, et al (2012). C-reaction protein as an adverse prognosis marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol, 30, 33-7.
  21. Freedland SJ, Sun L, Kane CJ, et al (2008). Obesity and oncologic outcome after radical prostatectomy: Impact of prostate-specific antigen-based prostate cancer screening: Results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center Databases. BJU International, 102, 969-74.
  22. Baillargeon J, Rose DP (2006). Obesity, adipokines, and prostate cancer. Int J Oncol, 28, 737-45.
  23. Buschemeyer WC, Freedland SJ (2007). Obesity and prostate cancer: Epidemiology and clinical implications. Eur Urol, 52, 331-43.
  24. Carroll PR (2003). Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Urol Oncol, 21, 484-5.
  25. Gallina A, Karakiewicz PI, Hutterer GC, et al (2007). Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in Europen men. Int J Cancer, 121, 791-5.
  26. Guo YZ, Pan L, Du CJ, et al (2013). Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8.
  27. Hsing AW, Sakoda LC, Chua S Jr (2007). Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr, 86, 843-57.
  28. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin , 61, 69-90.
  29. Kane CJ, Bassett WW, Sadetsky N, et al (2005). Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol, 173, 732-6.
  30. Loeb S, YU X, Nadler RB, et al (2007). Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol, 177, 102-6.
  31. Azevedo A, Cunha V, Teixeira AL, et al (2011). IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol, 2, 384-96.

Cited by

  1. Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis vol.13, pp.1, 2015,